BID and glioblastoma: Two studies have revealed that the proteasome inhibitor bortezomib primes GBM, including GBM stem cells, for TRAIL sensitization, which is dependent on increased tBid stability, mitochondrial apoptosis, and modulation of the NF-κB signaling pathway [38,133].